Braveheart Bio | $185,000,000 | (Nov 6, 2025)
CommanderAI | $5,000,000 | (Nov 6, 2025)
Procurement Sciences | $30,000,000 | (Nov 6, 2025)
Certified by Founder
Lodge
Tubulis GmbH
start up
Germany
- Munich, Bayern
- 16/10/2025
- Series C
- $359,197,300
Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.
- Industry Biotechnology Research
- Website https://tubulis.com/
- LinkedIn https://www.linkedin.com/company/tubulis/
Freeda | $3,912,210 | (Nov 6, 2025)
NEOK Bio | $75,000,000 | (Nov 6, 2025)
LambdaVision, Inc. | $7,000,000 | (Nov 6, 2025)
Flux XII Inc. | $3,950,000 | (Nov 6, 2025)
Boostie | $500,000 | (Nov 6, 2025)
Rilevera | $3,000,000 | (Nov 6, 2025)
Wisconsin Alumni Research Foundation (WARF) | $3,950,000 | (Nov 6, 2025)
Cactus | $7,000,000 | (Nov 6, 2025)
GitLaw | $30,000,000 | (Nov 6, 2025)